Are the mesothelial-to-mesenchymal transition, sclerotic peritonitis syndromes, and encapsulating peritoneal sclerosis part of the same process?
EntityUAM. Departamento de Medicina
PublisherHindawi Publishing Corporation
10.1155/2013/263285International Journal of Nephrology 2013 (2013): 263285
ISSN2090-214X (print); 2090-2158 (online)
Funded byThis work was supported by Grant SAF2010-21249 from the Ministerio de Economía y Competitividad to M. López- Cabrera and by Grant S2010/BMD-2321 from Comunidad Autónoma de Madrid to M. López-Cabrera and R. Selgas This work was also partially supported by Grants PI 09/0776 from Fondo de Investigaciones Sanitarias to A. A. Peralta and RETICS 06/0016 (REDinREN, Fondos FEDER, EU) to R. Selgas
ProjectComunidad de Madrid. S2010/BMD-2321/FIBROTEAM
SubjectsPeritoneal dialysis; Medicina
RightsCopyright © 2013 Jesus Loureiro et al.
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
Mesothelial-to-mesenchymal transition (MMT) is an autoregulated physiological process of tissue repair that in uncontrolled conditions, such as peritoneal dialysis (PD), can lead to peritoneal fibrosis. The maximumexpression of sclerotic peritoneal syndromes (SPS) is the encapsulating peritoneal sclerosis (EPS) for which no specific treatment exists. The SPS includes a wide range of peritoneal fibrosis that appears progressively and is considered as a reversible process, while EPS does not. EPS is a serious complication of PD characterized by a progressive intra-abdominal inflammatory process that results in bridles and severe fibrous tissue formation which cover and constrict the viscera. Recent studies show that transdifferentiated mesothelial cells isolated from the PD effluent correlate very well with the clinical events such as the number of hemoperitoneum and peritonitis, as well as with PD function (lower ultrafiltration and high Cr-MTC). In addition, in peritoneal biopsies from PD patients, the MMT correlates very well with anatomical changes (fibrosis and angiogenesis). However, the pathway to reach EPS from SPS has not been fully and completely established. Herein, we present important evidence pointing to the MMT that is present in the initial peritoneal fibrosis stages and it is perpetual over time, with at least theoretical possibility that MMT initiated the fibrosing process to reach EPS
Google Scholar:Loureiro, Jesús - González-Mateo, Guadalupe Tirma - Jiménez-Heffernan, José Antonio - Selgas Gutiérrez, Rafael - López-Cabrera, Manuel - Aguilera Peralta, Abelardo
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis Loureiro, Jesús; Sandoval, Pilar; Del Peso, Gloria D.; González-Mateo, Guadalupe Tirma; Fernández-Millara, Vanessa; Santamaría, Beatríz; Bajo, Auxiliadora; Sánchez-Tomero, José Antonio; Guerra-Azcona, Gonzalo; Selgas Gutiérrez, Rafael; López-Cabrera, Manuel; Aguilera, Abelardo I.
Functional relevance of the switch of VEGF receptors/co-receptors during peritoneal dialysis-induced mesothelial to mesenchymal transition Pérez-Lozano, María Luisa; Sandoval, Pilar; Rynne-Vidal, Ángela; Aguilera, Abelardo I.; Jiménez-Heffernan, José Antonio; Albar-Vizcaíno, Patricia; Majano, Pedro Lorenzo; Sánchez-Tomero, José Antonio; Selgas Gutiérrez, Rafael; López-Cabrera, Manuel
Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis Sandoval, Pilar; Jiménez-Heffernan, José Antonio; Rynne-Vidal, Ángela; Pérez-Lozano, María Luisa; Gilsanz, Álvaro; Ruiz-Carpio, Vicente; Reyes, Raquel; García-Bordas, Julio; Stamatakis, Konstantinos; Dotor, Javier; Majano, Pedro L.; Fresno, Manuel; Cabañas, Carlos; López-Cabrera, Manuel